Literature DB >> 21784177

Quantitative determination of the composition of multi-shell calcium phosphate-oligonucleotide nanoparticles and their application for the activation of dendritic cells.

V Sokolova1, T Knuschke, J Buer, A M Westendorf, M Epple.   

Abstract

Biodegradable calcium phosphate nanoparticles as carriers for the immunoactive toll-like receptor ligands CpG and polyinosinic-polycytidylic acid for the activation of dendritic cells (DC) combined with the viral antigen hemagglutinin (HA) were prepared. A purification method based on ultracentrifugation and ultrasonication was developed to separate the nanoparticles from dissolved biomolecules. The number of biomolecules, i.e., oligonucleotides and peptide, incorporated into the nanoparticles was quantitatively determined by UV-spectroscopy, using fluorescent derivatives of the biomolecules. The immunostimulatory effects of purified calcium phosphate nanoparticles on DC were studied, i.e., cytokine production and activation of the cells in terms of the upregulation of surface molecules. Purified calcium phosphate nanoparticles, i.e., without dissolved biomolecules, are capable of inducing adaptive immunity by activation of DC. Immunostimulatory effects of purified calcium phosphate nanoparticles on DC were demonstrated by increased expression of co-stimulatory molecules and MHC II and by cytokine secretion. In addition, DC treated with purified functionalized calcium phosphate nanoparticles induced an antigen-specific T-cell response in vitro.
Copyright © 2011 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784177     DOI: 10.1016/j.actbio.2011.07.010

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  8 in total

1.  The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization.

Authors:  Torben Knuschke; Matthias Epple; Astrid M Westendorf
Journal:  Hum Vaccin Immunother       Date:  2013-08-27       Impact factor: 3.452

2.  Inorganic nanovectors for nucleic acid delivery.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Anisha A D'Souza; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

Review 3.  Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis.

Authors:  Vuk Uskokovic
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2015       Impact factor: 4.889

Review 4.  Biodegradable calcium phosphate nanoparticles for cancer therapy.

Authors:  Razieh Khalifehzadeh; Hamed Arami
Journal:  Adv Colloid Interface Sci       Date:  2020-04-10       Impact factor: 12.984

5.  Calcium phosphate nanoparticles show an effective activation of the innate immune response in vitro and in vivo after functionalization with flagellin.

Authors:  Diana Kozlova; Viktoriya Sokolova; Maohua Zhong; Ejuan Zhang; Jingyi Yang; Wei Li; Yi Yang; Jan Buer; Astrid Maria Westendorf; Matthias Epple; Huimin Yan
Journal:  Virol Sin       Date:  2013-12-26       Impact factor: 4.327

6.  Delivery of the autofluorescent protein R-phycoerythrin by calcium phosphate nanoparticles into four different eukaryotic cell lines (HeLa, HEK293T, MG-63, MC3T3): Highly efficient, but leading to endolysosomal proteolysis in HeLa and MC3T3 cells.

Authors:  Mathis Kopp; Olga Rotan; Chrisovalantis Papadopoulos; Nina Schulze; Hemmo Meyer; Matthias Epple
Journal:  PLoS One       Date:  2017-06-06       Impact factor: 3.240

7.  Amiloride-enhanced gene transfection of octa-arginine functionalized calcium phosphate nanoparticles.

Authors:  Juan Ramón Vanegas Sáenz; Taichi Tenkumo; Yuya Kamano; Hiroshi Egusa; Keiichi Sasaki
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

8.  Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8+ T Cell Responses During Chronic Retroviral Infection.

Authors:  Torben Knuschke; Olga Rotan; Wibke Bayer; Sebastian Kollenda; Julia Dickow; Kathrin Sutter; Wiebke Hansen; Ulf Dittmer; Karl S Lang; Matthias Epple; Jan Buer; Astrid M Westendorf
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.